New hope for kids with tough brain tumors: gene therapy meets immunotherapy and radiation
NCT ID NCT07017816
First seen Apr 29, 2026 · Last updated Jun 19, 2026 · Updated 10 times
Summary
This early-phase trial is testing a combination of three treatments for children whose brain tumors have come back or not responded to standard care. The experimental drug SGT-53 delivers a normal TP53 gene to tumor cells, and is given alongside the immunotherapy Nivolumab and radiation therapy. The main goals are to find a safe dose of SGT-53 and to understand its side effects and how it moves through the body. Only 18 children will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PINEOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGT-53 (a drug that delivers a normal TP53 gene to cancer cells), Nivolumab (an immunotherapy), and radiation therapy
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat brain tumors that have come back or not responded to standard therapy.
What could go wrong
This is a very early (phase 0/1) and small trial (18 participants), so it is mainly testing safety and dosing. It may not show clear benefit, and side effects from the combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.